BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38348044)

  • 1. Gene expression meta-analysis reveals aging and cellular senescence signatures in scleroderma-associated interstitial lung disease.
    Yang MM; Lee S; Neely J; Hinchcliff M; Wolters PJ; Sirota M
    Front Immunol; 2024; 15():1326922. PubMed ID: 38348044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Expression Meta-Analysis Reveals Aging and Cellular Senescence Signatures in Scleroderma-associated Interstitial Lung Disease.
    Yang MM; Lee S; Neely J; Hinchcliff M; Wolters PJ; Sirota M
    bioRxiv; 2023 Nov; ():. PubMed ID: 37986995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
    Jung SM; Park KS; Kim KJ
    Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mapping of interstitial lung disease reveals a phenotypically distinct senescent basal epithelial cell population.
    DePianto DJ; Heiden JAV; Morshead KB; Sun KH; Modrusan Z; Teng G; Wolters PJ; Arron JR
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33705361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease.
    Valenzi E; Tabib T; Papazoglou A; Sembrat J; Trejo Bittar HE; Rojas M; Lafyatis R
    Front Immunol; 2021; 12():595811. PubMed ID: 33859634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis.
    Liu S; Chung MP; Ley B; French S; Elicker BM; Fiorentino DF; Chung LS; Boin F; Wolters PJ
    Thorax; 2021 Dec; 76(12):1186-1192. PubMed ID: 34272332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.
    Valenzi E; Bulik M; Tabib T; Morse C; Sembrat J; Trejo Bittar H; Rojas M; Lafyatis R
    Ann Rheum Dis; 2019 Oct; 78(10):1379-1387. PubMed ID: 31405848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
    Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
    Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.
    Stock CJW; De Lauretis A; Visca D; Daccord C; Kokosi M; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Nihtyanova S; Chua F; Maher TM; Ong V; Abraham DJ; Denton CP; Wells AU; Wain LV; Renzoni EA
    Clin Rheumatol; 2020 Apr; 39(4):1173-1179. PubMed ID: 31916109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-Selectin, ICAM-1, and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases.
    Pulito-Cueto V; Remuzgo-Martínez S; Genre F; Atienza-Mateo B; Mora-Cuesta VM; Iturbe-Fernández D; Lera-Gómez L; Mora-Gil MS; Portilla V; Corrales A; Blanco R; Cifrián JM; González-Gay MA; López-Mejías R
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.
    Mathai SK; Gulati M; Peng X; Russell TR; Shaw AC; Rubinowitz AN; Murray LA; Siner JM; Antin-Ozerkis DE; Montgomery RR; Reilkoff RA; Bucala RJ; Herzog EL
    Lab Invest; 2010 Jun; 90(6):812-23. PubMed ID: 20404807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
    Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
    Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature.
    Stock CJW; Renzoni EA
    Eur J Hum Genet; 2018 Jun; 26(6):765-777. PubMed ID: 29476163
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    He Y; Liu H; Wang S; Chen Y
    DNA Cell Biol; 2019 Sep; 38(9):933-944. PubMed ID: 31361540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.
    Akter T; Silver RM; Bogatkevich GS
    Curr Rheumatol Rep; 2014 Apr; 16(4):411. PubMed ID: 24523015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.
    Al-Adwi Y; Atzeni IM; Doornbos-van der Meer B; van der Leij MJ; Varkevisser RDM; Kroesen BJ; Stel A; Timens W; Gan CT; van Goor H; Westra J; Mulder DJ
    EBioMedicine; 2023 Dec; 98():104883. PubMed ID: 37995465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Netrin-1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin-Induced Pulmonary Fibrosis.
    Sun H; Zhu Y; Pan H; Chen X; Balestrini JL; Lam TT; Kanyo JE; Eichmann A; Gulati M; Fares WH; Bai H; Feghali-Bostwick CA; Gan Y; Peng X; Moore MW; White ES; Sava P; Gonzalez AL; Cheng Y; Niklason LE; Herzog EL
    Arthritis Rheumatol; 2016 May; 68(5):1251-61. PubMed ID: 26749424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
    Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
    Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cough is less common and less severe in systemic sclerosis-associated interstitial lung disease compared to other fibrotic interstitial lung diseases.
    Cheng JZ; Wilcox PG; Glaspole I; Corte TJ; Murphy D; Hague CJ; Ryerson CJ
    Respirology; 2017 Nov; 22(8):1592-1597. PubMed ID: 28544079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.